Zhongmin Tian

Prof. Zhongmin Tian

Xi'an Jiaotong University, Xi'an, China

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2018 in Molecules
Verified
Journal Article
Open access
PDF file
CZChen-Yang Zhao
Chen-Yang Zhao
RCRui Cheng
Rui Cheng
Zhe YangZhe Yang
Zhe Yang
ZTZhongmin Tian
Zhongmin Tian
Chemotherapy has been widely applied in clinics. However, the therapeutic potential of chemotherapy against cancer is seriously dissatisfactory due to the nonspecific drug distribution, multidrug resistance (MDR) and the heterogeneity of cancer. Therefore, combinational therapy based on chemotherapy mediated by nanotechnology, has been the trend in clinical research at present, which can result in a remarkably increased therapeutic efficiency with few side effects to normal tissues. Moreover, to achieve the accurate pre-diagnosis and real-time monitoring for tumor, the research of nano-theranostics, which integrates diagnosis with treatment process, is a promising field in cancer treatment. In this review, the recent studies on combinational therapy based on chemotherapy will be systematically discussed. Furthermore, as a current trend in cancer treatment, advance in theranostic nanoparticles based on chemotherapy will be exemplified briefly. Finally, the present challenges and improvement tips will be presented in combination therapy and nano-theranostics.

9 November 2020 in ACS Nano
Verified
Journal Article
Closed access
Zhe YangZhe Yang
Zhe Yang
DGDi Gao
Di Gao
XGXiaoqing Guo
Xiaoqing Guo
LJLin Jin
Lin Jin
JZJuanjuan Zheng
Juanjuan Zheng
ZTZhongmin Tian
Zhongmin Tian

5 January 2023 in Nature Reviews Clinical Oncology
Verified
Journal Article
Closed access
PDF file
Zhe YangZhe Yang
Zhe Yang
DGDi Gao
Di Gao
JZJing Zhao
Jing Zhao
GYGaojie Yang
Gaojie Yang
MGMing Guo
Ming Guo
XZXingcai Zhang
Xingcai Zhang

1 January 2020 in Materials Today Bio
Verified
Journal Article
Open access
YGYanzheng Gao
Yanzheng Gao
XGX. Guo
X. Guo
XZXingcai Zhang
Xingcai Zhang
SCS. Chen
S. Chen
YWY. Wang
Y. Wang
Zhe YangZhe Yang
Zhe Yang
Cancer, as one of the most life-threatening diseases, shows a high fatality rate around the world. When improving the therapeutic efficacy of conventional cancer treatments, researchers also conduct extensive studies into alternative therapeutic approaches, which are safe, valid, and economical. Phototherapies, including photodynamic therapy (PDT) and photothermal therapy (PTT), are tumor-ablative and function-reserving oncologic interventions, showing strong potential in clinical cancer treatment. During phototherapies, the non-toxic phototherapeutic agents can be activated upon light irradiation to induce cell death without causing much damage to normal tissues. Besides, with the rapid development of nanotechnology in the past decades, phototheranostic nanomedicine also has attracted tremendous interests aiming to continuously refine their performance. Herein, we reviewed the recent progress of phototheranostic nanomedicine for improved cancer therapy. After a brief introduction of the therapeutic principles and related phototherapeutic agents for PDT and PTT, the existing works on developing of phototheranostic nanomedicine by mainly focusing on their categories and applications, particularly on phototherapy-synergized cancer immunotherapy, are comprehensively reviewed. More importantly, a brief conclusion and future challenges of phototheranostic nanomedicine from our point of view are delivered in the last part of this article.

1 December 2017 in Biomaterials
Verified
Journal Article
Closed access
Zhe YangZhe Yang
Zhe Yang
NSNa Sun
Na Sun
RCRui Cheng
Rui Cheng
CZChenyang Zhao
Chenyang Zhao
ZLZerong Liu
Zerong Liu
ZTZhongmin Tian
Zhongmin Tian

11 February 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
ZTZhongmin Tian
Zhongmin Tian
MLMingyu Liang
Mingyu Liang
Hypertension is a leading risk factor for disease burden worldwide. The kidneys, which have a high specific metabolic rate, play an essential role in the long-term regulation of arterial blood pressure. In this review, we discuss the emerging role of renal metabolism in the development of hypertension. Renal energy and substrate metabolism is characterized by several important and, in some cases, unique features. Recent advances suggest that alterations of renal metabolism may result from genetic abnormalities or serve initially as a physiological response to environmental stressors to support tubular transport, which may ultimately affect regulatory pathways and lead to unfavorable cellular and pathophysiological consequences that contribute to the development of hypertension.